No hantavirus vaccine is expected to reach approval or licensure by the end of 2026, as all current candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Recent mRNA efforts by Moderna and partners, along with DNA vaccine research, have shown immunogenicity in animal models as of early 2025, yet these face extended safety testing, manufacturing scale-up, and regulatory review typical for orthohantavirus countermeasures. Outbreaks in 2026 have renewed attention but underscore the absence of licensed options outside limited Asian markets for older HFRS strains. Accelerated emergency pathways remain possible only with unprecedented funding or confirmed surges, though historical timelines and low disease incidence make rapid completion improbable before year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% 機率
$129,738 交易量
$129,738 交易量
2026-12-31
6% 機率
$129,738 交易量
$129,738 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is expected to reach approval or licensure by the end of 2026, as all current candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Recent mRNA efforts by Moderna and partners, along with DNA vaccine research, have shown immunogenicity in animal models as of early 2025, yet these face extended safety testing, manufacturing scale-up, and regulatory review typical for orthohantavirus countermeasures. Outbreaks in 2026 have renewed attention but underscore the absence of licensed options outside limited Asian markets for older HFRS strains. Accelerated emergency pathways remain possible only with unprecedented funding or confirmed surges, though historical timelines and low disease incidence make rapid completion improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市場開放時間： May 4, 2026, 10:39 AM ET
交易量
$129,738結束日期
2026-12-31市場開放時間
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is expected to reach approval or licensure by the end of 2026, as all current candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Recent mRNA efforts by Moderna and partners, along with DNA vaccine research, have shown immunogenicity in animal models as of early 2025, yet these face extended safety testing, manufacturing scale-up, and regulatory review typical for orthohantavirus countermeasures. Outbreaks in 2026 have renewed attention but underscore the absence of licensed options outside limited Asian markets for older HFRS strains. Accelerated emergency pathways remain possible only with unprecedented funding or confirmed surges, though historical timelines and low disease incidence make rapid completion improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$129,738結束日期
2026-12-31市場開放時間
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No hantavirus vaccine is expected to reach approval or licensure by the end of 2026, as all current candidates remain in preclinical or early-phase clinical stages with no Phase 3 trials underway. Recent mRNA efforts by Moderna and partners, along with DNA vaccine research, have shown immunogenicity in animal models as of early 2025, yet these face extended safety testing, manufacturing scale-up, and regulatory review typical for orthohantavirus countermeasures. Outbreaks in 2026 have renewed attention but underscore the absence of licensed options outside limited Asian markets for older HFRS strains. Accelerated emergency pathways remain possible only with unprecedented funding or confirmed surges, though historical timelines and low disease incidence make rapid completion improbable before year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions